secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001558370-25-001681
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock reports FY 2024 net loss of $2.47/share; BLA submitted for apitegromab in SMA
--------------------------------------------------------------------------------

- Net loss $246.3M ( $2.47 /share) vs $165.8M ( $1.99 /share) in FY 2023; zero revenue.
- Cash, equivalents & marketable securities $437.3M; expanded credit facility adds up to $150M in tranches.
- BLA for apitegromab in SMA submitted Jan 2025; US launch planned 4Q 2025; EU MAA expected 1Q 2025.
- Phase 2 EMBRAZE topline data (apitegromab+tirzepatide in obesity) expected 2Q 2025; IND for SRK-439 in 3Q 2025.
- COO/CFO Ted Myles departing; search for new CFO; Lisa Wyman appointed CTQO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/0001558370-25-001681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer